Inventor / Scientific Advisor

Gabriele Multhoff currently holds a C3 Professorship in Experimental Radiation Oncology/Radiation Biology at the Department of Radiation Oncology and Radiation Therapy at the Klinikum rechts der Isar, Technical University of Munich (TUM). She is also the Founder and CSO of the biotech company multimmune GmbH and is the named inventor on multiple granted patents relating to theranostics based on her discovery of membrane Hsp70 expression on tumor cells.

A key focus of Prof. Gabriele Multhoff’s research work is the development of innovative cell-, molecule- and antibody-based targeted immunotherapies based on targeting membrane Hsp70 on cancers – a concept which she discovered. Her research work has led to a randomized, multicenter clinical phase II study entitled “Targeted NK cell-based adjuvant immunotherapy for the treatment of patients with non-small cell lung carcinoma (NSCLC) after radiochemotherapy” funded by the German Federal Ministry of Education and Research (BMBF).

To stratify patients who most likely will benefit from membrane Hsp70-targeting therapies, her group established a novel screening test (EDx700^TM); patent granted) to quantify exosomal, tumor-derived Hsp70 and a method to isolate circulating tumor cells (CTCs) after mesenchymal transition in the blood of patients (EDX900^TM. Hsp70 in liquid biopsies provides a promising biomarker for viable tumor mass in different tumor entities and CTCs in the blood are presently evaluated as valuable tools for prediction of clinical responses and therapy resistance of cancer.

Gabriele is a Commissioner of the German Academic Exchange Service (DAAD) and the EU, as well as a member of numerous professional and scientific associations. Between 2007 and 2009 Gabriele was President of the “Cell Stress Society International” (CSSI).

Gabriele holds a Diploma in Biology and a PhD in Biology from the Ludwig-Maximilians-University Munich.